COMMUNIQUÉS West-GlobeNewswire

Aesthetics International Launches Medical-Grade Abdominoplasty Program to Help Address Chronic Back Pain
17/03/2026
Aesthetics International Redefines How ‘Tummy Tucks’ Are Solving Chronic Back Pain Through Core Muscle Repair DUBAI, United Arab Emirates, March 17, 2026 (GLOBE NEWSWIRE) -- Aesthetics International, a pioneer in [...]
Tecan to create Data-Driven Labs with NVIDIA
17/03/2026
Männedorf, Switzerland, March 17, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a strategic collaboration with NVIDIA focused on providing the AI-enabled platforms that Data-Driven Laboratories need [...]
Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference
16/03/2026
EAGLE, Idaho, March 16, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it [...]
Imprivata Introduces New Advanced Access Management and Passwordless Authentication Capabilities to Enhance Clinical Efficiency, Security, and Essential Eight Compliance
16/03/2026
Imprivata Enterprise Access Management now offers facial recognition, AI-powered behavioral analytics, and high-assurance identity verification to further streamline clinical access, improve operational efficiency, and [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/03/2026
WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
16/03/2026
BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
16/03/2026
CRANFORD, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
CMR Surgical Advances Physical AI to Support the Future of Robotic Surgery with NVIDIA
16/03/2026
Cambridge-based surgical robotics company contributes majority of surgical data to world’s largest open healthcare robotics dataset Cambridge, UK and San Jose, California – 16 March 2026, CMR Surgical (“CMR”), the [...]
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
16/03/2026
With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. The new computational infrastructure supports [...]
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
16/03/2026
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for [...]
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
16/03/2026
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an [...]
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
16/03/2026
Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline setting Company is preparing to initiate a [...]
LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC
16/03/2026
Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026 ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global [...]
Tobias Burkhardt’s Paretofit Reports 98.1% Success Rate Across 169 Entrepreneur Coaching Engagements
16/03/2026
Paretofit, founded by Tobias Burkhardt, reports a 98.1% documented success rate across 169 completed coaching engagements with entrepreneurs, founders, and self-employed professionals in the DACH region. Köln, NORDRHEIN [...]
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
16/03/2026
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – March 16, 2026 ( [...]
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
16/03/2026
-- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous variant of the [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
16/03/2026
RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
16/03/2026
Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing [...]
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
16/03/2026
Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness – CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseases Appointed industry veteran [...]

Pages